Literature DB >> 15709027

Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.

Thomas J Chambers1, Xiaofeng Fan, Deborah A Droll, Edgardo Hembrador, Tiffany Slater, Michael W Nickells, Lynn B Dustin, Adrian M Dibisceglie.   

Abstract

A series of 29 patients undergoing treatment for chronic hepatitis C virus (HCV) genotype 1 infection with pegylated alpha-2a interferon plus ribavirin were studied for patterns of response to antiviral therapy and viral quasispecies evolution. All patients were treatment naive and had chronic inflammation and fibrosis on biopsy. As part of an analysis of pretreatment variables that might affect the outcome of treatment, genetic heterogeneity within the viral E1-E2 glycoprotein region (nucleotides 851 to 2280) was assessed by sequencing 10 to 15 quasispecies clones per patient from serum-derived PCR products. Genetic parameters were examined with respect to response to therapy based on serum viral RNA loads at 12 weeks (early viral response) and at 24 weeks posttreatment (sustained viral response). Nucleotide and amino acid quasispecies complexities of the hypervariable region 1 (HVR-1) were less in the responder group in comparison to the nonresponder group at 12 weeks, and genetic diversity was also less both within and outside of the HVR-1, with the difference being most pronounced for the non-HVR-1 region of E2. However, these genetic parameters did not distinguish responders from nonresponders for sustained viral responses. Follow-up studies of genetic heterogeneity based on the HVR-1 in selected responders and nonresponders while on therapy revealed greater evolutionary drift in the responder subgroup. The pretreatment population sequences for the NS5A interferon sensitivity determinant region were also analyzed for all patients, but no correlations were found between treatment response and any distinct genetic markers. These findings support previous studies indicating a high level of genetic heterogeneity among chronically infected HCV patients. One interpretation of these data is that early viral responses are governed to some extent by viral factors, whereas sustained responses may be more influenced by host factors, in addition to effects of viral complexity and diversity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15709027      PMCID: PMC548442          DOI: 10.1128/JVI.79.5.3071-3083.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

Authors:  M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

2.  Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients.

Authors:  Y Kanazawa; N Hayashi; E Mita; T Li; H Hagiwara; A Kasahara; H Fusamoto; T Kamada
Journal:  Hepatology       Date:  1994-11       Impact factor: 17.425

3.  CLUSTAL: a package for performing multiple sequence alignment on a microcomputer.

Authors:  D G Higgins; P M Sharp
Journal:  Gene       Date:  1988-12-15       Impact factor: 3.688

4.  Variability of the envelope regions of HCV in European isolates and its significance for diagnostic tools.

Authors:  M Roggendorf; M Lu; K Fuchs; G Ernst; M Höhne; E Schreier
Journal:  Arch Virol Suppl       Date:  1993

5.  A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences.

Authors:  M Kimura
Journal:  J Mol Evol       Date:  1980-12       Impact factor: 2.395

6.  Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment.

Authors:  K Koizumi; N Enomoto; M Kurosaki; T Murakami; N Izumi; F Marumo; C Sato
Journal:  Hepatology       Date:  1995-07       Impact factor: 17.425

7.  Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C.

Authors:  R P González-Peralta; K Qian; J Y She; G L Davis; T Ohno; M Mizokami; J Y Lau
Journal:  J Med Virol       Date:  1996-07       Impact factor: 2.327

8.  Degree of diversity of hepatitis C virus quasispecies and progression of liver disease.

Authors:  M Honda; S Kaneko; A Sakai; M Unoura; S Murakami; K Kobayashi
Journal:  Hepatology       Date:  1994-11       Impact factor: 17.425

9.  Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.

Authors:  N Enomoto; I Sakuma; Y Asahina; M Kurosaki; T Murakami; C Yamamoto; Y Ogura; N Izumi; F Marumo; C Sato
Journal:  N Engl J Med       Date:  1996-01-11       Impact factor: 91.245

10.  Hepatitis C viral quasispecies in hepatitis C virus carriers with normal liver enzymes and patients with type C chronic liver disease.

Authors:  M Naito; N Hayashi; T Moribe; H Hagiwara; E Mita; Y Kanazawa; A Kasahara; H Fusamoto; T Kamada
Journal:  Hepatology       Date:  1995-08       Impact factor: 17.425

View more
  42 in total

1.  Divergent quasispecies evolution in de novo hepatitis C virus infection associated with bone marrow transplantation.

Authors:  Weihua Wang; Jianguo Lin; De Tan; Yanjuan Xu; Elizabeth M Brunt; Xiaofeng Fan; Adrian M Di Bisceglie
Journal:  Biochem Biophys Res Commun       Date:  2011-09-16       Impact factor: 3.575

2.  Quasispecies as predictive response factors for antiviral treatment in patients with chronic hepatitis C.

Authors:  Javier Salmerón; Paloma Muñoz De Rueda; Angela Ruiz-Extremera; Jorge Casado; Carlos Huertas; Maria Del Carmen Bernal; Luis Rodríguez; Angel Palacios
Journal:  Dig Dis Sci       Date:  2006-05       Impact factor: 3.199

Review 3.  Viral determinants of resistance to treatment in patients with hepatitis C.

Authors:  Anette Wohnsland; Wolf Peter Hofmann; Christoph Sarrazin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

4.  Hepatitis C hypervariable region 1: association of reduced selection pressure in african americans with treatment failure.

Authors:  Vicki M Park; Barbara C Mason; Julia Krushkal; Rongling Li; Caroline Riely; Jaquelyn Fleckenstein
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

Review 5.  Acute hepatitis C virus infection: a chronic problem.

Authors:  Jason T Blackard; M Tarek Shata; Norah J Shire; Kenneth E Sherman
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

Review 6.  Hepatitis C virus genetic variability and evolution.

Authors:  Natalia Echeverría; Gonzalo Moratorio; Juan Cristina; Pilar Moreno
Journal:  World J Hepatol       Date:  2015-04-28

Review 7.  Clinical impact of hepatitis B and C virus envelope glycoproteins.

Authors:  Hélène Jeulin; Aurélie Velay; John Murray; Evelyne Schvoerer
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

8.  Influence of quasispecies on virological responses and disease severity in patients with chronic hepatitis C.

Authors:  Deepak Kumar; Abdul Malik; Mohammad Asim; Anita Chakravarti; Rakha-H Das; Premashis Kar
Journal:  World J Gastroenterol       Date:  2008-02-07       Impact factor: 5.742

Review 9.  Sequence diversity of hepatitis C virus: implications for immune control and therapy.

Authors:  Joerg Timm; Michael Roggendorf
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

10.  Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factors.

Authors:  Verónica Saludes; Maria Alma Bracho; Oliver Valero; Mercè Ardèvol; Ramón Planas; Fernando González-Candelas; Vicente Ausina; Elisa Martró
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.